Authorities in Guangdong, China approved Guangzhou Baiyunshan Pharmaceutical's (SHA:600332) reduction and addition of drug production lines, according to a Thursday filing with the Shanghai Stock Exchange.
The changes include reducing the Building F production line in Guangzhou, China, where it produces its Huatuo Zaizao, Yifu Zhixue, and Jindan traditional Chinese pills, and adding the Building D production line for its Qingre Sanjie traditional Chinese tablets, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments